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K. Cassar,1* P. Bachoo,2 I. Ford,3 M. Greaves3 and J. Brittenden11Department of Vascular Surgery, University of Aberdeen, 2Vascular Unit, Aberdeen Royal Infirmary, and
3Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, ScotlandObjectives. Patients with peripheral arterial disease have a significantly increased risk of cardiovascular and
cerebrovascular mortality. Studies have shown that some haemostatic and inflammatory markers are elevated in these
patients but the effect of the severity of the disease has not been fully documented. The aim of this study was to assess the level
of coagulation activation, endothelial stimulation and inflammation in patients with claudication and critical limb
ischaemia (CLI) compared to healthy controls.
Design and methods. A prospective observational study was conducted amongst 202 subjects: 132 claudicants, 30 patients
with critical ischaemia, and 40 controls. D-dimer (DD) and thrombin–antithrombin III (TAT) levels measured using ELISA
as markers of coagulation activation. vonWillebrand factor (vWF) and high-sensitivity C-reactive protein (CRP) levels were
measured as markers of endothelial and inflammatory stimulation.
Results. vWF and CRP levels were significantly higher in patients with intermittent claudication (1.9 U/ml, range 0.78–
4.05; p!0.001; 3.4 mg/l, range 0.15–24; pO0.001, respectively) and critical ischaemia (2.36 U/ml; range 1.03–5.69; p!
0.001; 7.17 mg/ml, range 0.15–174; p!0.001, respectively) compared to controls (1.28 U/ml, range 0.62–3.13; 1.04, range
0.15–7.59 mg/l). DD was also significantly higher in claudicants (48.6 mg/ml; range 2–1741; p!0.001) and in patients
with CLI (61.1 mg/ml, range 3.65–1963; p!0.001) compared to controls (26.1 mg/ml, range 9.65–203.1). TAT levels were
significantly higher in CLI (3.14 mg/l, range 2.09–58.11), compared to controls (2.36 mg/l, range 1.49–7.38; pZ0.004).
Patients with CLI had significantly higher levels of CRP, vWF, and TAT than claudicants.
Conclusions. Coagulation activation and endothelial stimulation are significantly increased in patients with peripheral
arterial disease compared to healthy controls. Coagulation and endothelial activation increases with the severity of the
arterial disease.Keywords: Haemostasis; Thrombosis and vascular biology; Peripheral arterial disease.Introduction
Patients with peripheral arterial disease have a
significantly increased mortality due to cardiovascular
and cerebrovascular events.1–3 The underlying patho-
physiological process leading to these events is
atherothrombosis and thromboembolism.4,5 This
involves endothelial damage and changes at the site
of atherosclerosis leading to platelet adhesion, aggre-
gation and activation together with activation of
coagulation.6 The end product of this process ising author. K. Cassar MD, FRCS, Ward 36, Vascular
en Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN,
: k.cassar@abdn.ac.uk
0171+ 06 $35.00/0 q 2004 Elsevier Ltd. All rights reserocclusive thrombus which leads to ischaemia of the
organ supplied.7
We have recently shown platelet activation to be
increased in patients with intermittent claudication
and critical limb ischaemia compared to healthy
controls.8
Whether, this increased level of activation is
primary or secondary to the atherosclerotic changes
in these patients is uncertain. Patients with peripheral
arterial disease are known to have widespread
atherosclerotic changes in the coronary and cerebral
vessels which mirror the changes observed in the
peripheral vasculature.3
In addition to platelet activation, endothelial and
coagulation activation have been implicated in the
increased incidence of ischaemic events in patients
with peripheral arterial disease.8–15 However, whereasEur J Vasc Endovasc Surg 29, 171–176 (2005)
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peripheral arterial disease the use of anti-coagulants is
less extensive.16 Many large trials have shown that in
patients with peripheral arterial disease the use of the
anti-platelet agent aspirin is associated with a 25% risk
reduction of further serious adverse events.16 Few
studies have examined the role of anticoagulants in
patients with peripheral arterial disease.
Several studies have shown that haemostatic
markers are elevated in patients with peripheral
arterial disease.10–15 However, these studies aremainly
in claudicants and the effect of the severity of the
disease has not been fully documented and further
research is required in this area. Furthermore, little is
known about the status and role of inflammatory
markers such as CRP in patients with peripheral
arterial disease. The aim of this study was to assess the
level of coagulation activation and endothelial stimu-
lation in patients with intermittent claudication and
critical limb ischaemia compared to healthy controls.Methods
Participants to the study were recruited from patients
referred to the Vascular Unit, Aberdeen Royal Infirm-
ary. Patients with a history and clinical evidence of
intermittent claudication presenting at the Vascular
clinic were recruited to the study. The diagnosis of
intermittent claudication was confirmed by ankle–
brachial pressure index (!0.9) and duplex evidence of
peripheral vascular disease. Patients with tissue loss
(gangrene or ulceration) of the lower limbs secondary
to ischaemia admitted to the vascular unit were
recruited. Confirmation of severe limb ischaemia as
the cause of tissue loss was made by measurement of
ankle–brachial pressure index (!0.5) and duplex
evidence of peripheral arterial disease. All patients
with claudication or critical limb ischaemia were
receiving 75 mg aspirin at recruitment.
Healthy controls were recruited from patients
referred to the Vascular clinic with varicose veins
and who had no history of ischaemic heart disease,
cerebrovascular disease or peripheral arterial disease.
All controls had normal ankle–brachial pressure
indices. None of the controls was receiving aspirin.
Informed consent was obtained from each subject
and full ethical approval for the study was sought and
granted by the Grampian Research Ethics Committee.
Exclusion criteria: patients were excluded if their
haemoglobin was less than 100 g/l, platelet count
less than 150!109/l, creatinine more than twice the
upper limit of normal, aspartate aminotransferase,
alkaline phosphatase or gamma glutamyl transferaseEur J Vasc Endovasc Surg Vol 29, February 2005more than three times the upper limit of normal and if
the body mass index exceeded 33. Patients with a
history of haematological malignancy, acute illness
unrelated to peripheral arterial disease within 14 days,
transfusion of whole blood within 14 days, known or
suspected alcohol or drug abuse or on warfarin,
steroids or clopidogrel were also excluded.Blood investigations
Blood samples were withdrawn from the antecubital
vein of rested subjects by clean venpuncture and
plasma was stored at K80 8C until assayed. All
samples were done in duplicate, with double stan-
dards and quality control. Von Willebrand factor
(vWF) and high sensitivity C-reactive protein (CRP)
were measured as markers of endothelial and inflam-
matory stimulation. D-dimer and thrombin–antith-
rombin III (TAT) levels were measured as markers of
coagulation activation. vWF was measured by an
in-house ELISA using polyclonal rabbit-antihuman
vWF antibody and horse radish peroxidase-conju-
gated antibody from Dako Ltd, Denmark.17 The inter-
assay variation varied between 1.3 and 8.6%, whereas
the inter-assay coefficient of variation ranged between
2.9 and 10.1%.
High sensitivity CRP was measured using an
immunoturbidimetric assay (Dade Behring, France)
with high sensitivity at the Biochemistry laboratory,
Aberdeen Royal Infirmary. The coefficient of variation
ranged between 1.2 and 2.68%.
TATcomplex levels were measured using an ELISA
kit (Enzygnost TAT micro, Dade Behring Marburg
GmbH, Marburg, Germany). This covered a concen-
tration range of 2–60 mg/l. The intra-assay coefficient
of variation fell between 4 and 6% whereas the inter-
assay coefficient of variation was between 6 and 9%.
D-dimer was measured using an ELISA kit
(Dimertest Gold EIA kit, Agen) with an intra-assay
coefficient of variation ranging from 3.7 to 6.8%. The
inter-assay coefficient of variation ranged from 6.6 to
10.1%.Statistical analysis
Results are presented as median values with range.
Calculations were performed using SPSS for Windows
version 10.0 statistical software. Differences between
controls, claudicants and patients with critical limb
ischaemia were analysed using the Mann–Whitney U
test. A p-value of less than 0.05 was considered
significant.
Coagulation, Endothelial Stimulation, Inflammation 173ResultsSubjects
Two hundred and two subjects were recruited to the
study, 132 patients with intermittent claudication, 30
patients with critical limb ischaemia and 40 controls.
Themean age was 52.8 years for controls, 65.8 years for
claudicants and 72.1 years for patients with critical
ischaemia. Table 1 shows the sex distribution, smoking
habits and other demographic details of subjects
recruited.Fig. 1. Boxplots of C-reactive protein levels in controls,
claudicants and criticals. (BarsZmedian values; WhiskersZ
smallest and largest values excluding extremes; top of boxC
75th percentile; bottom of boxZ25th percentile). *Statisti-
cally significant difference.Coagulation activation and endothelial stimulation in
peripheral arterial disease compared to controls
Figs. 1–4 show the results for D-dimer, TAT, CRP and
vWF in controls, claudicants and criticals. Results are
shown as median values with 25th and 75th percen-
tiles. CRP and vWF were significantly elevated in
patients with intermittent claudication (3.4 mg/l,
range 0.15–24, p!0.001; 1.9 U/ml, range 0.78–4.05,
p!0.001, respectively) compared to controls (1.04 mg/l,
range 015–7.59 and 1.28 U/ml, range 0.62–3.13,
respectively). Similarly, both CRP and vWF were
significantly higher in patients with critical ischaemia
(7.17 mg/l, range 0.15–174, p!0.001; 2.36 U/ml, range
1.03–5.69, p!0.001, respectively) compared to con-
trols. Furthermore both CRP (pZ0.001) and vWF (pZ
0.005) were significantly higher in patients with critical
ischaemia compared to patients with intermittent
claudication.
D-dimer was found to be significantly higher in
both patients with intermittent claudication
(48.6 mg/ml, range 2–1741, p!0.001) and those withTable 1. Basic demographics of patients in the three groups
Controls
(nZ40)
Claudicants
(nZ132)
Criticals
(nZ30)
Sex ratio (M:F) 2:3 3.4:1 1.3:1
Smoking n (%)
Current 10 (25) 45 (34.1) 13 (40.6)
Stopped!1
year
0 (0) 24 (18.2) 3 (9.4)
StoppedO1
year
15 (37.5) 55 (41.7) 13 (40.6)
Never
smoked
15 (37.5) 8 (6.1) 3 (9.4)
Diabetics n
(%)
0 (0) 23 (17.4) 14 (43.8)
History of
CHD
0 20 (15.2%) 7 (23%)
Treated
hypertension
0 51 (38.6%) 12 (40%)
Age/years
(STD)
52.7 (13.9) 65.7 (8.4) 73.2 (8.7)critical ischaemia (61.1 mg/ml, range 3.65–1963, p!
0.001) compared to controls (26.1 mg/ml, range 9.65–
203.1). The difference in D-dimer between claudicants
and criticals, however, failed to reach statistical
significance (pZ0.08). Similarly, TAT levels were
found to be significantly elevated in patients with
critical ischaemia (3.14 mg/l, range 2.09–58.11, pZ
0.004) compared to controls (2.36 mg/l, range 1.49–
7.38). There was no significant difference, however,
between claudicants (2.41 mg/l, range 1.24–63.22, pZ
0.48) and controls in TAT levels.Fig. 2. Boxplots of von Willebrand factor levels in controls,
claudicants and criticals. (BarsZmedian values; WhiskersZ
smallest and largest values excluding extremes; top of boxC
75th percentile; bottom of boxZ25th percentile). *Statisti-
cally significant difference.
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Fig. 3. Boxplots of D-dimer levels in controls, claudicants
and criticals. (BarsZmedian values; WhiskersZsmallest and
largest values excluding extremes; top of boxC75th percen-
tile; bottom of boxZ25th percentile). *Statistically significant
difference.
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This study demonstrates that patients with peripheral
arterial disease have enhanced coagulation activation
as well as evidence of on going endothelial activation
compared to controls. This may be associated with the
increased risk of cardiovascular and cerebrovascular
events observed in this group of patients. The results
also show that the more severe the extent of peripheral
arterial disease, the more coagulation activation and
endothelial activation is observed. Hence, patients
with critical ischaemia had significantly higher levels
of CRP, vWF, and TAT compared to patients with
intermittent claudication. This is consistent with the
fact that patients with critical ischaemia also have a
significantly higher risk of ischaemic events andFig. 4. Boxplots of TAT levels in controls, claudicants and
criticals. (BarsZmedian values; WhiskersZsmallest and
largest values excluding extremes; top of boxC75th percen-
tile; bottom of boxZ25th percentile). *Statistically significant
difference.
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ant finding as previous studies which have assessed
hemostatic and inflammatory markers have concen-
trated mainly on patients with ankle–brachial indexes
(ABI) less than 0.913,15,18 and data on patients with
critical limb ischaemia is limited. Although, there are
other markers of both inflammation and coagulation
available, selection of D-dimer, TAT, CRP and vWF
was based on experience with these markers and
previous validation.
In contrast to studies involving patients with
coronary artery disease there are only a limited
number of studies which have assessed CRP levels
in patients with peripheral arterial disease. Minor
elevations of CRP have been shown to be predictive of
cardiovascular events in patients with coronary heart
disease.19 It is now believed that CRP is not merely a
marker of low grade chronic systemic inflammation
but may be actively involved in atherosclerosis as it
can amplify the inflammatory response through
complement activation, tissue damage and activation
of endothelial cells.20 Recently, Ridker and colleagues
have shown CRP levels to be a strong predictor of
future cardiovascular events based on a study of
28,000 women.21 McDermott and colleagues, have
recently shown that CRP was not associated with
ankle–brachial pressure index in patients without a
history of cardiac or cerebrovascular disease.18 We
have shown that CRP levels are elevated in claudicants
and even more so in patients with critical limb
ischaemia. It should be known that only 15% of the
patients with claudication had a history of known
coronary heart disease. The finding of increased CRP
levels in claudicants and even more so in patients with
critical limb ischaemia, reflects the increased risk of
cardiac events and emphasises the need for these
patients to receive appropriate secondary risk factor
management.22 We found no difference between males
and females in each of the three groups with regards to
CRP and vWF levels.
In the Edinburgh Artery Study, elevated plasma
levels of vWF were significantly associated with the
risk of developing PAD, but not with the progression
of the disease.15 We have shown that patients with
claudication had significantly higher levels of vWF
than controls and levels were further significantly
increased in patients with critical limb ischaemia.
Levels of vWF have also been shown to be increased in
smokers and patients suffering from hypertension or
diabetes where it is considered to reflect endothelial
activation.23–25 In our study, there was no difference in
the smoking or hypertensive history in claudicants
and patients with critical limb ischaemia. There, were
however, more diabetics in the groupwith critical limb
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Subgroup analysis of patients with claudication and
no history of diabetes revealed that vWF were still
significantly increased compared to controls. It should
also be noted that the three groups of patients were not
matched in terms of age due to the need to recruit
control patients with no history of coronary artery
disease and the fact that critical limb ischaemia is more
common in older patients. Levels of vWF have been
shown to increase by 0.15 U/ml for each 10 years of
age.26 Allowing for this correction factor, vWF levels
were still significantly higher in patients with claudi-
cation compared to controls and even higher in
criticals. CRP levels also increase with age, but again
the differences observed between the groups are very
much larger that that which could be attributed to age
alone.27 Furthermore, the difference in both vWF and
CRP levels with age may be due to an increased
preponderance of vascular disease.
Various markers of coagulation, including the fibrin
degradation product D-dimer have been shown to be
elevated in patients with peripheral arterial disease. D-
dimer levels have also been shown to relate to the
severity of the atherosclerosis.13 McDermott and
colleagues have recently shown that D-dimer is
inversely associated with the ankle–brachial pressure
in patients with and without a history of cardiac or
cerebrovascular disease.18 We have found D-dimer
levels to be elevated in claudicants compared to
controls and have shown that levels are higher in
patients with critical limb ischaemia although this did
not reach statistical significance. With regards to the
fact that controls were not receiving aspirin in contrast
to both patients with claudication and patients with
critical ischaemia, D-dimer does not seem to be
affected by aspirin treatment.28,29
Elevated TAT levels have also been reported in
some smaller studies of patients with peripheral
arterial disease. However, a recent study of 131
patients showed no correlation between TAT levels
and the presence of peripheral arterial disease.13 We,
also found that this marker of thrombin generation
was not significantly increased in claudicants but was
significantly elevated in patients with critical limb
ischaemia. However, administration of aspirin reduces
TAT levels30,31 and, therefore, the fact that patients
with claudication and critical ischaemia were receiv-
ing aspirin while controls were not, indicates that the
difference between patients and controls may have
been underestimated.
We have previously shown that platelet activation is
significantly increased in patients with peripheral
arterial disease compared to controls despite aspirin
therapy.8 Current strategies to reduce the risk ofcardiovascular and cerebrovascular events in patients
with PAD consist mainly of antiplatelet treatment.32 If
the enhanced levels of coagulation activation observed
in patients with peripheral arterial disease play a part
in the increased risk in PAD then the implications are
that anticoagulants should be added to antiplatelet
treatment. Adding anticoagulant drugs to the cur-
rently recommended antiplatelet treatment may
reduce the risk of ischaemic events observed in this
group of patients but would also increase the risk of
bleeding. The use of this combined therapy has been
advocated in patients undergoing coronary angio-
plasty.33,34
In summary, this study adds to existing evidence for
the presence of a hypercoagulable state in patients
with peripheral arterial disease. This is even more
marked in patients with critical limb ischaemia
compared to those with claudication. Whether this
increased level of activation is primary or secondary to
the atherosclerotic changes in these patients is uncer-
tain. However, the findings that platelet function as
well as markers of coagulation and endothelial
stimulation are increased in patients with peripheral
arterial disease suggest that further research into use
of combined antiplatelet and anticoagulation therapy
is required in this group of patients.References
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